|Bid||192.99 x 200|
|Ask||193.04 x 600|
|Day's Range||192.13 - 193.60|
|52 Week Range||166.58 - 199.91|
|PE Ratio (TTM)||N/A|
|Expense Ratio (net)||0.09%|
It is often said that large-caps, many of which are multi-national firms generating significant portions of their revenue overseas, benefit from a weak dollar while smaller companies, due to their domestic ...
Globus Medical (GMED) is a medical device company with a focus on designing, developing, and commercializing musculoskeletal solutions. Globus Medical’s sales force is comprised of direct sales representatives and distributor sales representatives employed by exclusive independent distributors. Of the 13 analysts covering Globus Medical in February 2018, seven of them have given the stock a “buy” or higher rating.
It may be surprising to hear that in a year in which ETFs are shattering all sorts of records with regard to the amount of money they are taking in, the world's largest exchange-traded fund isn't participating in the bonanza. That's right; the SPDR S&P 500 ETF Trust (SPY), the $242 billion behemoth, has actually had net outflows this year to the tune of $4.2 billion.
In April 2017, United Therapeutics (UTHR) and 3D Systems (DDD) declared their plans to develop solid organ scaffolds for human transplants.
Any negative news from the jobs report will be foreshadowed by the tax reform news. It's the last jobs report before the September FOMC meeting.
In 1Q17, Bioverativ reported revenues close to $259.0 million, driven by its focus on a commercial strategy for its hemophilia products and optimal cost management.
Abiomed is primarily focused on the growth opportunity in the protected PCI area, a procedure that is applicable for patients with coronary artery disease.
In March 2017, Abiomed (ABMD) submitted premarket approval (or PMA) to the FDA for its Impella RP device far ahead of schedule.
PTEN's management believes that its merger with Seventy Seven Energy has consolidated PTEN’s position in drilling and pressure pumping activity.
In 2016, United Therapeutics (UTHR) reported ~$1.6 billion in revenues, reflecting ~9.0% YoY growth. In 1Q17, UTHR generated ~$370.0 million in revenues—an ~9.0% quarter-over-quarter decline.
NorthCoast's top holdings concentrated in U.S. and European equities continued to gain ground in Q2.
Align Technology (ALGN) is a medical device provider focused on malocclusion or teeth misalignment condition.
Abram Claude, Vice President, Learning Center Statistically, baby boomer women will outlive their husbands, and yet boomer men generally have higher Social Security benefits. A strategy that considers both spouses can maximize a couple’s benefits and ...
In 2Q17, management expects Patterson-UTI Energy (PTEN) to operate 84 rigs under term contracts, compared to 81 in 1Q17.